Human chemokine MIP1α increases efficiency of targeted DNA fusion vaccines (Q42834113)

8 November 2017

title

Human chemokine MIP1α increases efficiency of targeted DNA fusion vaccines (English)

1 reference

8 November 2017

Bjarne Bogen

1 reference

8 November 2017

Pier Adelchi Ruffini

1 reference

8 November 2017

Gunnveig Grødeland

1 reference

8 November 2017

Agnete B Fredriksen

series ordinal

1 reference

8 November 2017

language of work or name

English

0 references

publication date

4 November 2010

1 reference

8 November 2017

1 reference

8 November 2017

1 reference

8 November 2017

1 reference

8 November 2017

page(s)

191-199

1 reference

Heterologous protection against influenza by injection of DNA encoding a viral protein

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

DNA vaccines: ready for prime time?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Current progress of DNA vaccine studies in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Targeting antigens to dendritic cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Delivery of antigen to CD40 induces protective immune responses against tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Antibody‐mediated delivery of antigen to chemokine receptors on antigen‐presenting cells results in enhanced CD4+ T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

The CC chemokine ligand 3 regulates CD11c+CD11b+CD8alpha- dendritic cell maturation and activation following viral infection of the central nervous system: implications for a role in T cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Chemokine receptor-mediated delivery of mycobacterial MPT51 protein efficiently induces antigen-specific T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Restricted alpha/beta receptor gene usage of idiotype-specific major histocompatibility complex-restricted T cells: selection for CDR3-related sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Affinity labeling of a mouse myeloma protein which binds nitrophenyl ligands. Kinetics of labeling and isolation of a labeled peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Molecular characterization of covalent complexes between tissue transglutaminase and gliadin peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Production of interferon-gamma during infection of mice with Plasmodium chabaudi chabaudi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Macrophage inflammatory protein-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Regulation of chemokine activity by posttranslational modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Mobilization of dendritic cell precursors into the circulation by administration of MIP-1alpha in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Immune responses to an adjuvant-free native syngeneic myeloma protein (M315).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Cutaneous injection of human subjects with macrophage inflammatory protein-1 alpha induces significant recruitment of neutrophils and monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1α (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

Chemokine receptor antagonists: overcoming developmental hurdles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.057

10.1016/J.VACCINE.2010.10.057

7 January 2021

Identifiers

DOI

1 reference

8 November 2017

1 reference